Last $18.84 USD
Change Today +0.06 / 0.32%
Volume 120.2K
As of 3:15 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

12212 Technology Boulevard

Austin, TX 78727

United States

Phone: 512-219-8020

Fax: 512-219-5195

Luminex Corporation develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The company’s xMAP (Multi-Analyte Profiling) technology, an open architecture, multiplexing technology, allows simultaneous analysis of approximately 500 bioassays from a small sample volume, typically a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, light emitting diodes (LEDs), digital signal processors, photo detectors, charge-coupled device imaging and proprietary software to create a system offering advantages in speed, precision, flexibility and cost. The company’s xMAP technology is being used within various segments of the life sciences industry, which includes the fields of drug discovery and development, and for clinical diagnostics, genetic analysis, bio-defense, food safety and biomedical research. In addition to its xMAP technology, the company’s other offerings include its proprietary MultiCode technology, used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays, as well as automation and robotics in the field of dry sample handling. Segments The company’s segments include the Technology and Strategic Partnerships (TSP) and the Assays and Related Products (ARP). TSP This segment builds around strategic partnerships. The company licenses its xMAP technology to its partners, who then develop products that incorporate the xMAP technology into products that they sell to end users. The company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells these products to its partners. When its partners sell xMAP-based reagent consumable products or xMAP-based testing services, which run on the xMAP instrumentation, to end users, such as testing laboratories, the company obtains a royalty on the sales from the partner. ARP This segment is primarily involved in the development and sale of assays utilizing xMAP and xTAG technology on the company’s installed base of systems along with its MultiCode technology. The ARP segment is primarily focused on multiplexed applications for the human molecular clinical diagnostics market. The company’s ARP segment products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease. xMAP Technology The company’s xMAP technology combines existing biological testing techniques with illumination, advanced digital signal processing, detection and proprietary software. With its technology, discrete bioassays are performed on the surface of color-coded microspheres. These microspheres are read in a compact analyzer that utilizes lasers or LEDs, detectors and high-speed digital signal processing to simultaneously identify the bioassay and measure the individual assay results. The company purchases and manufactures microspheres and, in a proprietary process, dyes them with varying intensities of proprietary dyes to achieve up to 500 distinct colors. Its customers create bioassays by attaching different biochemical reactants to each distinctly colored microsphere set. These reactants bind, or capture, specific substances present in the test sample. The microsphere sets can then be combined in test panels as required by the user, with a maximum of 500 tests per panel. Customers can order either standard microspheres or magnetic microspheres. To perform a bioassay using xMAP technology on the company’s flow cytometry platforms, a researcher attaches biochemicals, or reagents, to one or more sets of color-coded microspheres, which are then mixed with a test sample. This mixture is injected into the xMAP analyzer, such as the Luminex 200 instrument, or LX200, where the microspheres pass single-file in a fluid stream through two laser beams. The second laser excites a fluorescent dye captured on the surface of the microspheres that is used to quantify the r

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMNX:US $18.84 USD +0.06

LMNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LMNX.
View Industry Companies
 

Industry Analysis

LMNX

Industry Average

Valuation LMNX Industry Range
No financial data is available for LMNX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUMINEX CORP, please visit www.luminexcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.